1. In Vivo
  2. >>Deal-Making

Biopharma Dealmaking Quarterly Statistics, Q4 2013

A look at financing, M&A, and alliance activity October–December 2013

Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.

Biopharma financings in the last quarter of 2013 reached $6.4 billion, an increase of 39% over Q3’s $4.6 billion, thanks to a large boost from debt financings. The fourth quarter – the second-largest quarter of the year in terms of dollars raised – helped push 2013’s total to $26.6 billion, way above 2012’s $13.6 billion. (See Exhibit 1.) Almost half of 2013’s total came from Q2’s $11 billion take, which is largely attributed to Valeant Pharmaceuticals International Inc.’s concurrent $2.3 billion follow-on public offering [See Deal] and $3.2 billion sale of debt [See Deal] to fund its $8.7 billion acquisition of Bausch & Lomb Inc.[See Deal]

Exhibi

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.